APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Dosage Form Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Solid Dosage Form Drug Market Analysis and Forecast 2026-2032

21 December 2025204 pages

Choose your research edition.

Industry ResearchSolid Dosage Form Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Dosage Form Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Solid Dosage Form Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Dosage Form Drug Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Dosage Form Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Solid Dosage Form Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Solid Dosage Form Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Solid Dosage Form Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Solid Dosage Form Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Solid Dosage Form Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Solid Dosage Form Drug include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly & Co., Pfizer and GlaxoSmithKline, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Solid Dosage Form Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Solid Dosage Form Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Solid Dosage Form Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Solid Dosage Form Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Solid Dosage Form Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Solid Dosage Form Drug revenue, projected growth trends, production technology, application and end-user industry.

Solid Dosage Form Drug Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly & Co.

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol Myers Squibb

Amgen

AbbVie

AstraZeneca

Merck & Co.

Gilead Sciences

Boehringer Ingelheim

Astellas

Solid Dosage Form Drug Segment by Type

Tablet

Capsules

Other

Solid Dosage Form Drug Segment by Application

Hospital

Retail Pharmacy

Other

Solid Dosage Form Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Dosage Form Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Dosage Form Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Dosage Form Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Solid Dosage Form Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Solid Dosage Form Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Solid Dosage Form Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Solid Dosage Form Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablet Major Player Table 3. Capsules Major Player Table 4. Other Major Player Table 5. Global Solid Dosage Form Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Retail Pharmacy Major Player Table 8. Other Major Player Table 9. Solid Dosage Form Drug Industry Trends Table 10. Solid Dosage Form Drug Industry Drivers Table 11. Solid Dosage Form Drug Industry Opportunities and Challenges Table 12. Solid Dosage Form Drug Industry Restraints Table 13. Global Solid Dosage Form Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Solid Dosage Form Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Solid Dosage Form Drug Market Share by Region (2021-2026) Table 16. Global Solid Dosage Form Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Solid Dosage Form Drug Market Share by Region (2027-2032) Table 18. Global Solid Dosage Form Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Solid Dosage Form Drug Revenue Market Share by Players (2021-2026) Table 20. Global Solid Dosage Form Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Solid Dosage Form Drug Key Players Headquarters & Area Served Table 22. Global Solid Dosage Form Drug Players, Product Type & Application Table 23. Global Solid Dosage Form Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Solid Dosage Form Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Solid Dosage Form Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Solid Dosage Form Drug Revenue Market Share by Type (2021-2026) Table 30. Global Solid Dosage Form Drug Revenue Market Share by Type (2027-2032) Table 31. Global Solid Dosage Form Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Solid Dosage Form Drug Revenue Market Share by Application (2021-2026) Table 35. Global Solid Dosage Form Drug Revenue Market Share by Application (2027-2032) Table 36. Takeda Company Information Table 37. Takeda Business Overview Table 38. Takeda Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Solid Dosage Form Drug Product Portfolio Table 40. Takeda Recent Development Table 41. Teva Company Information Table 42. Teva Business Overview Table 43. Teva Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Teva Solid Dosage Form Drug Product Portfolio Table 45. Teva Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Solid Dosage Form Drug Product Portfolio Table 50. Sanofi Recent Development Table 51. Johnson & Johnson Company Information Table 52. Johnson & Johnson Business Overview Table 53. Johnson & Johnson Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Johnson & Johnson Solid Dosage Form Drug Product Portfolio Table 55. Johnson & Johnson Recent Development Table 56. Novartis Company Information Table 57. Novartis Business Overview Table 58. Novartis Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Novartis Solid Dosage Form Drug Product Portfolio Table 60. Novartis Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Solid Dosage Form Drug Product Portfolio Table 65. Roche Recent Development Table 66. Eli Lilly & Co. Company Information Table 67. Eli Lilly & Co. Business Overview Table 68. Eli Lilly & Co. Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Eli Lilly & Co. Solid Dosage Form Drug Product Portfolio Table 70. Eli Lilly & Co. Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Solid Dosage Form Drug Product Portfolio Table 75. Pfizer Recent Development Table 76. GlaxoSmithKline Company Information Table 77. GlaxoSmithKline Business Overview Table 78. GlaxoSmithKline Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. GlaxoSmithKline Solid Dosage Form Drug Product Portfolio Table 80. GlaxoSmithKline Recent Development Table 81. Biogen Company Information Table 82. Biogen Business Overview Table 83. Biogen Solid Dosage Form Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Biogen Solid Dosage Form Drug Product Portfolio Table 85. Biogen Recent Development Table 86. Bayer Company Information Table 87. Bayer Business Overview Table 88. Bayer Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Bayer Solid Dosage Form Drug Product Portfolio Table 90. Bayer Recent Development Table 91. Bristol Myers Squibb Company Information Table 92. Bristol Myers Squibb Business Overview Table 93. Bristol Myers Squibb Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Bristol Myers Squibb Solid Dosage Form Drug Product Portfolio Table 95. Bristol Myers Squibb Recent Development Table 96. Amgen Company Information Table 97. Amgen Business Overview Table 98. Amgen Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Amgen Solid Dosage Form Drug Product Portfolio Table 100. Amgen Recent Development Table 101. AbbVie Company Information Table 102. AbbVie Business Overview Table 103. AbbVie Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. AbbVie Solid Dosage Form Drug Product Portfolio Table 105. AbbVie Recent Development Table 106. AstraZeneca Company Information Table 107. AstraZeneca Business Overview Table 108. AstraZeneca Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. AstraZeneca Solid Dosage Form Drug Product Portfolio Table 110. AstraZeneca Recent Development Table 111. Merck & Co. Company Information Table 112. Merck & Co. Business Overview Table 113. Merck & Co. Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Merck & Co. Solid Dosage Form Drug Product Portfolio Table 115. Merck & Co. Recent Development Table 116. Gilead Sciences Company Information Table 117. Gilead Sciences Business Overview Table 118. Gilead Sciences Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Gilead Sciences Solid Dosage Form Drug Product Portfolio Table 120. Gilead Sciences Recent Development Table 121. Boehringer Ingelheim Company Information Table 122. Boehringer Ingelheim Business Overview Table 123. Boehringer Ingelheim Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Boehringer Ingelheim Solid Dosage Form Drug Product Portfolio Table 125. Boehringer Ingelheim Recent Development Table 126. Astellas Company Information Table 127. Astellas Business Overview Table 128. Astellas Solid Dosage Form Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Astellas Solid Dosage Form Drug Product Portfolio Table 130. Astellas Recent Development Table 131. North America Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. North America Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. North America Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Solid Dosage Form Drug Revenue by Country (2021-2026) & (US$ Million) Table 137. North America Solid Dosage Form Drug Revenue by Country (US$ Million) & (2027-2032) Table 138. Europe Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 139. Europe Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 140. Europe Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. Europe Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. Europe Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Solid Dosage Form Drug Revenue by Country (2021-2026) & (US$ Million) Table 144. Europe Solid Dosage Form Drug Revenue by Country (US$ Million) & (2027-2032) Table 145. China Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 146. China Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 147. China Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 148. China Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Asia Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Solid Dosage Form Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Asia Solid Dosage Form Drug Revenue by Region (US$ Million) & (2021-2026) Table 155. Asia Solid Dosage Form Drug Revenue by Region (US$ Million) & (2027-2032) Table 156. SAMEA Solid Dosage Form Drug Revenue by Type (2021-2026) & (US$ Million) Table 157. SAMEA Solid Dosage Form Drug Revenue by Type (2027-2032) & (US$ Million) Table 158. SAMEA Solid Dosage Form Drug Revenue by Application (2021-2026) & (US$ Million) Table 159. SAMEA Solid Dosage Form Drug Revenue by Application (2027-2032) & (US$ Million) Table 160. SAMEA Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. SAMEA Solid Dosage Form Drug Revenue by Country (2021-2026) & (US$ Million) Table 162. SAMEA Solid Dosage Form Drug Revenue by Country (US$ Million) & (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Solid Dosage Form Drug Image Figure 2. Global Solid Dosage Form Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Dosage Form Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablet Image Figure 5. Capsules Image Figure 6. Other Image Figure 7. Global Solid Dosage Form Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Solid Dosage Form Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Retail Pharmacy Image Figure 11. Other Image Figure 12. Global Solid Dosage Form Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Solid Dosage Form Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Solid Dosage Form Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Solid Dosage Form Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Solid Dosage Form Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Solid Dosage Form Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Solid Dosage Form Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Solid Dosage Form Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Solid Dosage Form Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Solid Dosage Form Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Solid Dosage Form Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Solid Dosage Form Drug Revenue Share by Type (2021-2032) Figure 25. North America Solid Dosage Form Drug Revenue Share by Application (2021-2032) Figure 26. North America Solid Dosage Form Drug Revenue Share by Country (2021-2032) Figure 27. United States Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Solid Dosage Form Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Solid Dosage Form Drug Revenue Share by Type (2021-2032) Figure 32. Europe Solid Dosage Form Drug Revenue Share by Application (2021-2032) Figure 33. Europe Solid Dosage Form Drug Revenue Share by Country (2021-2032) Figure 34. Germany Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Solid Dosage Form Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Solid Dosage Form Drug Revenue Share by Type (2021-2032) Figure 44. China Solid Dosage Form Drug Revenue Share by Application (2021-2032) Figure 45. Asia Solid Dosage Form Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Solid Dosage Form Drug Revenue Share by Type (2021-2032) Figure 47. Asia Solid Dosage Form Drug Revenue Share by Application (2021-2032) Figure 48. Asia Solid Dosage Form Drug Revenue Share by Region (2021-2032) Figure 49. Japan Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Solid Dosage Form Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Solid Dosage Form Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Solid Dosage Form Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Solid Dosage Form Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Solid Dosage Form Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsules
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly & Co.
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Merck & Co.
  • Gilead Sciences
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Solid Dosage Form Drug Market by Type
  3. 1.2.1 Global Solid Dosage Form Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablet
  5. 1.2.3 Capsules
  6. 1.2.4 Other
  7. 1.3 Solid Dosage Form Drug Market by Application
  8. 1.3.1 Global Solid Dosage Form Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Retail Pharmacy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Solid Dosage Form Drug Market Dynamics
  1. 2.1 Solid Dosage Form Drug Industry Trends
  2. 2.2 Solid Dosage Form Drug Industry Drivers
  3. 2.3 Solid Dosage Form Drug Industry Opportunities and Challenges
  4. 2.4 Solid Dosage Form Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Solid Dosage Form Drug Market Perspective (2021-2032)
  2. 3.2 Global Solid Dosage Form Drug Growth Trends by Region
  3. 3.2.1 Global Solid Dosage Form Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Solid Dosage Form Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Solid Dosage Form Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Solid Dosage Form Drug Revenue by Players
  2. 4.1.1 Global Solid Dosage Form Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Solid Dosage Form Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Solid Dosage Form Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Solid Dosage Form Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Solid Dosage Form Drug Key Players Headquarters & Area Served
  7. 4.4 Global Solid Dosage Form Drug Players, Product Type & Application
  8. 4.5 Global Solid Dosage Form Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Solid Dosage Form Drug Market CR5 and HHI
  11. 4.6.3 2025 Solid Dosage Form Drug Tier 1, Tier 2, and Tier 3
5 Solid Dosage Form Drug Market Size by Type
  1. 5.1 Global Solid Dosage Form Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 5.3 Global Solid Dosage Form Drug Revenue Market Share by Type (2021-2032)
6 Solid Dosage Form Drug Market Size by Application
  1. 6.1 Global Solid Dosage Form Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Solid Dosage Form Drug Revenue by Application (2021-2032)
  3. 6.3 Global Solid Dosage Form Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Solid Dosage Form Drug Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Solid Dosage Form Drug Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Solid Dosage Form Drug Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Solid Dosage Form Drug Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Solid Dosage Form Drug Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Solid Dosage Form Drug Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Eli Lilly & Co.
  38. 7.7.1 Eli Lilly & Co. Company Information
  39. 7.7.2 Eli Lilly & Co. Business Overview
  40. 7.7.3 Eli Lilly & Co. Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly & Co. Solid Dosage Form Drug Product Portfolio
  42. 7.7.5 Eli Lilly & Co. Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Solid Dosage Form Drug Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 GlaxoSmithKline
  50. 7.9.1 GlaxoSmithKline Company Information
  51. 7.9.2 GlaxoSmithKline Business Overview
  52. 7.9.3 GlaxoSmithKline Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GlaxoSmithKline Solid Dosage Form Drug Product Portfolio
  54. 7.9.5 GlaxoSmithKline Recent Developments
  55. 7.10 Biogen
  56. 7.10.1 Biogen Company Information
  57. 7.10.2 Biogen Business Overview
  58. 7.10.3 Biogen Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Biogen Solid Dosage Form Drug Product Portfolio
  60. 7.10.5 Biogen Recent Developments
  61. 7.11 Bayer
  62. 7.11.1 Bayer Company Information
  63. 7.11.2 Bayer Business Overview
  64. 7.11.3 Bayer Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bayer Solid Dosage Form Drug Product Portfolio
  66. 7.11.5 Bayer Recent Developments
  67. 7.12 Bristol Myers Squibb
  68. 7.12.1 Bristol Myers Squibb Company Information
  69. 7.12.2 Bristol Myers Squibb Business Overview
  70. 7.12.3 Bristol Myers Squibb Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bristol Myers Squibb Solid Dosage Form Drug Product Portfolio
  72. 7.12.5 Bristol Myers Squibb Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Amgen Solid Dosage Form Drug Product Portfolio
  78. 7.13.5 Amgen Recent Developments
  79. 7.14 AbbVie
  80. 7.14.1 AbbVie Company Information
  81. 7.14.2 AbbVie Business Overview
  82. 7.14.3 AbbVie Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AbbVie Solid Dosage Form Drug Product Portfolio
  84. 7.14.5 AbbVie Recent Developments
  85. 7.15 AstraZeneca
  86. 7.15.1 AstraZeneca Company Information
  87. 7.15.2 AstraZeneca Business Overview
  88. 7.15.3 AstraZeneca Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AstraZeneca Solid Dosage Form Drug Product Portfolio
  90. 7.15.5 AstraZeneca Recent Developments
  91. 7.16 Merck & Co.
  92. 7.16.1 Merck & Co. Company Information
  93. 7.16.2 Merck & Co. Business Overview
  94. 7.16.3 Merck & Co. Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Merck & Co. Solid Dosage Form Drug Product Portfolio
  96. 7.16.5 Merck & Co. Recent Developments
  97. 7.17 Gilead Sciences
  98. 7.17.1 Gilead Sciences Company Information
  99. 7.17.2 Gilead Sciences Business Overview
  100. 7.17.3 Gilead Sciences Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Gilead Sciences Solid Dosage Form Drug Product Portfolio
  102. 7.17.5 Gilead Sciences Recent Developments
  103. 7.18 Boehringer Ingelheim
  104. 7.18.1 Boehringer Ingelheim Company Information
  105. 7.18.2 Boehringer Ingelheim Business Overview
  106. 7.18.3 Boehringer Ingelheim Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Boehringer Ingelheim Solid Dosage Form Drug Product Portfolio
  108. 7.18.5 Boehringer Ingelheim Recent Developments
  109. 7.19 Astellas
  110. 7.19.1 Astellas Company Information
  111. 7.19.2 Astellas Business Overview
  112. 7.19.3 Astellas Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Astellas Solid Dosage Form Drug Product Portfolio
  114. 7.19.5 Astellas Recent Developments
8 North America
  1. 8.1 North America Solid Dosage Form Drug Revenue (2021-2032)
  2. 8.2 North America Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Solid Dosage Form Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Solid Dosage Form Drug Revenue by Type (2027-2032)
  5. 8.3 North America Solid Dosage Form Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Solid Dosage Form Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Solid Dosage Form Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Solid Dosage Form Drug Revenue by Application (2027-2032)
  9. 8.5 North America Solid Dosage Form Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Solid Dosage Form Drug Revenue by Country
  11. 8.6.1 North America Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Solid Dosage Form Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Solid Dosage Form Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Solid Dosage Form Drug Revenue (2021-2032)
  2. 9.2 Europe Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Solid Dosage Form Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Solid Dosage Form Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Solid Dosage Form Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Solid Dosage Form Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Solid Dosage Form Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Solid Dosage Form Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Solid Dosage Form Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Solid Dosage Form Drug Revenue by Country
  11. 9.6.1 Europe Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Solid Dosage Form Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Solid Dosage Form Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Solid Dosage Form Drug Revenue (2021-2032)
  2. 10.2 China Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Solid Dosage Form Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Solid Dosage Form Drug Revenue by Type (2027-2032)
  5. 10.3 China Solid Dosage Form Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Solid Dosage Form Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Solid Dosage Form Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Solid Dosage Form Drug Revenue by Application (2027-2032)
  9. 10.5 China Solid Dosage Form Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Solid Dosage Form Drug Revenue (2021-2032)
  2. 11.2 Asia Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Solid Dosage Form Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Solid Dosage Form Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Solid Dosage Form Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Solid Dosage Form Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Solid Dosage Form Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Solid Dosage Form Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Solid Dosage Form Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Solid Dosage Form Drug Revenue by Country
  11. 11.6.1 Asia Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Solid Dosage Form Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Solid Dosage Form Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Solid Dosage Form Drug Revenue (2021-2032)
  2. 12.2 SAMEA Solid Dosage Form Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Solid Dosage Form Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Solid Dosage Form Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Solid Dosage Form Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Solid Dosage Form Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Solid Dosage Form Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Solid Dosage Form Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Solid Dosage Form Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Solid Dosage Form Drug Revenue by Country
  11. 12.6.1 SAMEA Solid Dosage Form Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Solid Dosage Form Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Solid Dosage Form Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst